Alzamend Neuro (ALZN) Competitors $3.40 +0.11 (+3.34%) Closing price 05/16/2025 04:00 PM EasternExtended Trading$3.33 -0.07 (-2.06%) As of 05/16/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ALZN vs. CYBN, SLS, NLTX, ACRS, EPRX, NKTX, GLSI, LRMR, ADCT, and TARAShould you be buying Alzamend Neuro stock or one of its competitors? The main competitors of Alzamend Neuro include Cybin (CYBN), SELLAS Life Sciences Group (SLS), Neoleukin Therapeutics (NLTX), Aclaris Therapeutics (ACRS), Eupraxia Pharmaceuticals (EPRX), Nkarta (NKTX), Greenwich LifeSciences (GLSI), Larimar Therapeutics (LRMR), ADC Therapeutics (ADCT), and Protara Therapeutics (TARA). These companies are all part of the "pharmaceutical products" industry. Alzamend Neuro vs. Cybin SELLAS Life Sciences Group Neoleukin Therapeutics Aclaris Therapeutics Eupraxia Pharmaceuticals Nkarta Greenwich LifeSciences Larimar Therapeutics ADC Therapeutics Protara Therapeutics Alzamend Neuro (NASDAQ:ALZN) and Cybin (NYSE:CYBN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their community ranking, institutional ownership, valuation, analyst recommendations, media sentiment, earnings, profitability, risk and dividends. Is ALZN or CYBN more profitable? Alzamend Neuro's return on equity of 0.00% beat Cybin's return on equity.Company Net Margins Return on Equity Return on Assets Alzamend NeuroN/A N/A -289.14% Cybin N/A -37.58%-36.59% Does the MarketBeat Community prefer ALZN or CYBN? Cybin received 10 more outperform votes than Alzamend Neuro when rated by MarketBeat users. CompanyUnderperformOutperformAlzamend NeuroOutperform Votes7100.00% Underperform VotesNo VotesCybinOutperform Votes17100.00% Underperform VotesNo Votes Do insiders and institutionals believe in ALZN or CYBN? 49.6% of Alzamend Neuro shares are owned by institutional investors. Comparatively, 17.9% of Cybin shares are owned by institutional investors. 30.2% of Alzamend Neuro shares are owned by insiders. Comparatively, 15.0% of Cybin shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has more volatility & risk, ALZN or CYBN? Alzamend Neuro has a beta of -0.16, suggesting that its stock price is 116% less volatile than the S&P 500. Comparatively, Cybin has a beta of 0.6, suggesting that its stock price is 40% less volatile than the S&P 500. Do analysts recommend ALZN or CYBN? Alzamend Neuro currently has a consensus price target of $180.00, suggesting a potential upside of 5,194.12%. Cybin has a consensus price target of $86.00, suggesting a potential upside of 1,179.76%. Given Alzamend Neuro's higher probable upside, research analysts clearly believe Alzamend Neuro is more favorable than Cybin.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alzamend Neuro 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Cybin 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 Which has preferable earnings & valuation, ALZN or CYBN? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlzamend NeuroN/AN/A-$9.95MN/AN/ACybinN/AN/A-$57.88M-$4.38-1.53 Does the media refer more to ALZN or CYBN? In the previous week, Alzamend Neuro had 1 more articles in the media than Cybin. MarketBeat recorded 4 mentions for Alzamend Neuro and 3 mentions for Cybin. Cybin's average media sentiment score of 0.72 beat Alzamend Neuro's score of 0.31 indicating that Cybin is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alzamend Neuro 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cybin 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryCybin beats Alzamend Neuro on 7 of the 13 factors compared between the two stocks. Get Alzamend Neuro News Delivered to You Automatically Sign up to receive the latest news and ratings for ALZN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALZN vs. The Competition Export to ExcelMetricAlzamend NeuroPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.72M$6.44B$5.35B$8.52BDividend YieldN/A2.67%4.95%4.12%P/E RatioN/A9.1626.9119.99Price / SalesN/A247.33389.29119.38Price / CashN/A65.8538.2534.62Price / Book-0.976.456.764.60Net Income-$9.95M$143.73M$3.23B$248.61M7 Day Performance-42.60%4.47%4.88%5.14%1 Month Performance-43.62%7.93%9.92%13.67%1 Year Performance-94.04%-5.48%14.89%6.77% Alzamend Neuro Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALZNAlzamend Neuro3.0637 of 5 stars$3.40+3.3%$180.00+5,194.1%-94.2%$2.72MN/A0.004News CoverageGap DownCYBNCybin2.5832 of 5 stars$6.57-0.8%$86.00+1,210.0%N/A$141.00MN/A-1.5050News CoverageAnalyst UpgradeSLSSELLAS Life Sciences Group0.9088 of 5 stars$1.50-2.9%N/A+10.9%$140.88M$1M-2.1610News CoverageEarnings ReportGap UpNLTXNeoleukin TherapeuticsN/A$14.73-1.8%N/A-42.3%$138.43MN/A-4.7490News CoverageGap DownHigh Trading VolumeACRSAclaris Therapeutics2.7732 of 5 stars$1.27+1.2%$10.67+743.2%+11.0%$136.98M$18.72M-2.43100Analyst ForecastAnalyst RevisionEPRXEupraxia Pharmaceuticals2.9314 of 5 stars$3.82+0.5%$10.50+174.9%+30.2%$136.94MN/A-5.3129Gap UpNKTXNkarta2.0724 of 5 stars$1.92-5.2%$14.83+674.6%-74.5%$135.96MN/A-1.02140News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionGLSIGreenwich LifeSciences1.2278 of 5 stars$9.71+1.3%$39.00+301.9%-32.6%$128.82MN/A-12.133Positive NewsLRMRLarimar Therapeutics1.9487 of 5 stars$1.97-5.1%$19.63+894.2%-73.4%$127.16MN/A-1.7330News CoveragePositive NewsADCTADC Therapeutics2.698 of 5 stars$1.28-4.9%$7.75+507.8%-54.2%$126.45M$70.84M-0.53310News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionTARAProtara Therapeutics2.5222 of 5 stars$3.23-1.2%$20.40+531.6%-14.7%$125.38MN/A-1.1530 Related Companies and Tools Related Companies Cybin Competitors SELLAS Life Sciences Group Competitors Neoleukin Therapeutics Competitors Aclaris Therapeutics Competitors Eupraxia Pharmaceuticals Competitors Nkarta Competitors Greenwich LifeSciences Competitors Larimar Therapeutics Competitors ADC Therapeutics Competitors Protara Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALZN) was last updated on 5/17/2025 by MarketBeat.com Staff From Our PartnersThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alzamend Neuro, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alzamend Neuro With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ALZN Stock Free ALZN Stock Alerts